Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765068 | 0.80 | PIK3CD (0.40) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL3757536 | 0.78 | PIK3CA (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL3759850 | 0.71 | PIK3CA (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL3760548 | 0.71 | PIK3CD (0.42) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL3764700 | 0.70 | PIK3CA (0.42) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL3758728 | 0.70 | PIK3CA (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL3764741 | 0.70 | PIK3CA (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL3764964 | 0.70 | PIK3CA (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL3766105 | 0.70 | PIK3CA (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL3760335 | 0.70 | PIK3CA (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | PIK3CD 9/4885PIK3CA 3/4885PIK3CB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.